# Vishal Gulati

> Vishal Gulati is a seed investor at Frameshift (London) backing Biotechnology and Biopharma. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Frameshift](https://shizune.co/investors/profile/frameshift)
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Aug 2023
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/vgulat
- X (Twitter): http://twitter.com/vgul
- Website: https://x.com/vgul

Vishal Gulati is a seed investor at Frameshift in London focused on Biotechnology and Biopharma. Vishal Gulati: Vishal serves as a venture partner specialising in digital health at DFJ Esprit, Europe's leading Silicon Valley style venture capital firm with over $1b under management. Since 2012, Vishal has been Europe’s leading promoter of investment into the emerging digital health sector and chairman of Digital Health Forum, whichsupports the best in class digital health companies to grow into global enterprises. Vishal serves on several boards including Horizon Discovery Group PLC (Cambridge, UK), a gene editing company; Fluidics Analytics (Cambridge, UK), a next gen protein discovery engine, Frameshift a healthcare information flow platform (London, UK) and EcoEos (San Francisco, USA), a consumer genomics business. His previous investments include Napo Pharmaceuticals, Glenmark, Renovo and Phagenesis.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3.2M–$8M |
| Series A | $2.1M–$12M |
| Series B | $6.8M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Biopharma | 3 | 38% |
| Life Science | 3 | 38% |
| Pharmaceutical | 2 | 25% |
| Artificial Intelligence | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 25% |
| Series A | 2 | 25% |
| Series B | 2 | 25% |
| Pre-Seed | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 50% |
| Hungary | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Verisian | Accelerate drug time to market through real study traceability and unparalleled trial integrity | $1.3M | Pre-Seed | Aug 17, 2023 |  |
| evonetix | evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $30M | Series B | Mar 02, 2020 |  |
| Turbine | Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $3.2M | Seed | Nov 06, 2019 |  |
| Arctoris | Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic. | $8M | Seed | Jul 01, 2019 |  |
| evonetix | evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $12.3M | Series A | Jan 30, 2018 |  |
| ieso | ieso is a provider of online mental health therapy and develops clinically evidenced assessment and treatment products. ieso's breakthrough discoveries transforms mental healthcare and is revolutionising how the world sees mental health.ieso is building globally scalable digital products and therapeutics for the assessment and treatment ofcommon mood disorders with an additional focus on behaviorally modifiable chronic diseases. | $23.6M |  | Sep 12, 2017 |  |
| Fluidic Analytics | Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge.Their roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitabletools for protein characterisation. So they decided to invent their own.Their vision is that protein science will transform their understanding of how the biological world operates in real time. They believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed their understanding of how the biological world operates over decades, lifetimes and generations. And they believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life.They've combined cutting edge technology, a fantastic team and best practice in management and communication to go from their founding to a customer ready prototype in 2 years. And they’re only just beginning. This instrument is just the first step towards a platform technology that will serve as the interface between the biological and digital world – as they continue to expand what is possible for their customers.Their desire for accessibility and openness is present in their company’s culture of communication and integrity, in the usability of their products, in their open exchange of ideas with their collaborators and in their commitment to their users complete ownership of their own data. They believe that in working this way, they have the opportunity to create not just a company, but a community that fundamentally improves how they live. | $6.8M | Series B | Sep 06, 2016 |  |
| Fluidic Analytics | Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge.Their roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitabletools for protein characterisation. So they decided to invent their own.Their vision is that protein science will transform their understanding of how the biological world operates in real time. They believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed their understanding of how the biological world operates over decades, lifetimes and generations. And they believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life.They've combined cutting edge technology, a fantastic team and best practice in management and communication to go from their founding to a customer ready prototype in 2 years. And they’re only just beginning. This instrument is just the first step towards a platform technology that will serve as the interface between the biological and digital world – as they continue to expand what is possible for their customers.Their desire for accessibility and openness is present in their company’s culture of communication and integrity, in the usability of their products, in their open exchange of ideas with their collaborators and in their commitment to their users complete ownership of their own data. They believe that in working this way, they have the opportunity to create not just a company, but a community that fundamentally improves how they live. | $2.1M | Series A | Dec 18, 2014 |  |

8 of 8 investments shown.

## Co-investors
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 2 deals together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 2 deals together
- [DCVC](https://shizune.co/investors/profile/data-collective) — VC Fund, 2 deals together
- [IQ Capital](https://shizune.co/investors/profile/iq-capital-partners) — VC Fund, 2 deals together
- [Rising Tide](https://shizune.co/investors/profile/rising-tide-fund) — VC Fund, 2 deals together
- [University of Cambridge Enterprise](https://shizune.co/investors/profile/university-of-cambridge-enterprise) — VC Fund, 2 deals together

## About Frameshift

VC Fund · London, United Kingdom

Frameshift is a technology platform matching professionals with temporary work assignments.

5 contacts available at Frameshift.

| Name | Title | Profile |
| --- | --- | --- |
| Carlos F. Santos | Managing Partner | https://shizune.co/investors/profile/carlos-f-santos-2 |
| Forrest Cox | Partner | https://shizune.co/investors/profile/forrest-cox |
| Jonathan Feldmann | Partner | https://shizune.co/investors/profile/jonathan-p-feldmann |
| Stuart Lawson | CFO | https://shizune.co/investors/profile/stuart-lawson-2 |
| Vishal Gulati | Director | https://shizune.co/investors/profile/vishal-gulati |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Hiventures](https://shizune.co/investors/profile/hiventures) — VC Fund
- [Portfolion](https://shizune.co/investors/profile/portfolion) — VC Fund
- [Bonitás Ventures](https://shizune.co/investors/profile/bonit%C3%A1s-venture-capital-fund) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in Europe](https://shizune.co/investors/biotech-angel-investors-europe)
- [Biotechnology Angel Investors in Europe](https://shizune.co/investors/biotechnology-angel-investors-europe)
- [All Angel Investors in Hungary](https://shizune.co/investors/angel-investors-hungary)
- [Software Investors in Hungary](https://shizune.co/investors/software-investors-hungary)
- [Software Angel Investors in Hungary](https://shizune.co/investors/software-angel-investors-hungary)
- [Health Care Investors in Hungary](https://shizune.co/investors/health-care-investors-hungary)

## FAQ

### What does Vishal Gulati invest in?

Vishal Gulati invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Vishal Gulati's check size?

Vishal Gulati typically joins rounds of $3.2M–$8M at Seed, $2.1M–$12M at Series A and $6.8M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vishal Gulati participates in.

### When did Vishal Gulati last invest?

The most recent investment recorded for Vishal Gulati closed in Aug 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co